Objective:To compare the effect of 5 methionine-related media on inhibition of gastric cancer cells' proliferation. Methods:Gastric cancer cell line SUN-16 was cultured with L-Met,Met~(-)Hcy~(-),Met~(-)Hcy~(+),D-Met,and DL-Met media respectively.The group of L-Met medium was control.A_(490) was detected by MTT in 24,48,72,96,120 h. Results:Comparing with control group,A_(490) of SUN-16 cells significantly decreased in Met~(-)Hcy~(-),Met~(-)Hcy~(+),D-Met,DL-Met media respectively((P

0 05) 3 hours after myocardial infarction,and remarkably decreased (P

Objective To inquire into the effects of cardiac ? 1 -adrenergic receptor on myocardial remodeling and modulating calcium channel. Methods The models of myocardial remodeling after myocardial infarction in Wistar rats were used to study the expression changes of cardiac collagen subtype Ⅰ,Ⅲ,fibronectin (FN) with immunohistochemistry,and changes of T-type calcium channel,L-type calcium channel and ? 1 -adrenergic receptor mRNA expressions by reverse transcription and polymerase chain reaction(RT-PCR) and in situ hybridization. Cardiac total Ca 2+ was tested by atomic absorption/flame emission spectrophotometer. Results Cardiac collagenⅠ,collagen Ⅲ,FN protein expressions in betaloc group were remarkably decreased (P

Objective To inquire into the correlation of cardiac AT 1 receptor,? 1 receptor with PKC/MAPKs(protein kinase C/mitogen-activated protein kinase) signal transduction pathway during myocardial remodeling.Methods Twenty-four Wistar rats were randomly divided into four groups-sham group,infarcted group,losartan group and betaloc group.Except sham group,left anterior descending coronary artery was ligated for 21 days.In the other three groups,expression changes of cardiac collagen subtype Ⅰ,Ⅲ,fibronectin(FN),c-fos,ERK 1 (extracellular signal-regulated kinase,ERK)and PKC proteins were studied with immunohistochemistry and computer image analysis. c-fos mRNA expression was tested by reverse transcription and polymerase chain reaction(RT-PCR).Results Expressions of collagen Ⅰ,collagen Ⅲ , FN,c-fos,ERK 1 and PKC proteins were significantly enhanced(P

Many malignant tumor have methionine dependency. Methionine restriction can inhibit proliferation of tumors cells by decreasing the level of methionine with depriving methionine, methioninase, homocysteine, and its analogs.Methionine restriction may act synergistically with chemotherapies to increase their efficiency and /or reduce their toxic side effects.Therefore, methionine restriction would become a new cancer treatment.

It is reported that plenty of men,especially the aged,have been bothering in penile erectile dysfunction(ED).There are series of treatments for ED.Oral erectogenic agents have become the first-line treatment options,including drugs that act on the central and peripheral nervous systems,testosterone,traditional Chinese medicine and so on.Sidenafil,apomorphine and yohimbine are the only three oral therapies currently available for the treatment of this disorder.The second therapy includes intracavernosum injection,transurethral medications,transdermal medications etc.Intracavernosum injection of PGE 1 is an effective approach at the present.With the rapid understanding of erectile physiology and etiology of ED and the introduction of new effective oral agents,the future of pharmacotherapy for ED will extend.In this review,we have highlighted the advances in current treatments and therapeutic approaches in male erectile dysfunction.

Sidenafil, a potent inhibitor of phosphodiesterase Ⅴ, has been used to treat clinical erectile dysfunction(ED) and brings hope for them. But it is not effective for all ED patients, especially for some special types of ED, and the side effects, complications and contraindications exist still. Recent years, with the development of life qualities and medical conditions, patients of ED hope the doctor can treat them appropriately according to the type of ED. However, in order to treat ED appropriately, the etiology of every type of ED must be further explored. The specialists of andrology have made endeavor in the fields, and obtained some new knowledges.

Objective Mapping the sites of earliest activation in AF patients with rheumatic heart disease. Finding out the ratio of AF originate from the pulmonary veins. Methods There were 9 patients with valvular atrial fibrillation (1 male, 8 females age (42?13) years, histories of rheumatic heart disease (11?9) years, and mitral valve area 1.01?0.02 cm2) involved in the research. 3 patients had organized thrombus in left atrial appendage. 6 patients with persistent AF received anticoagulation therapy (warfarin 2 or 3 weeks) and drug cardioversion (amiodarone 400 mg, three times per day, for 7 days) before procedures, while other 3 patients with paroxysmal AF received neither anticoagulation therapy nor drug cardioversion. All patients received percutaneous balloon mitral valvotomy (PBMV). After finished PBMV, four multipolar electrode catheters were placed in the high right atrium (HRA), coronary sinus (CS), left atrium (LA) and pulmonary veins (PVs). S1S2 and S1S2S3 programmed stimuli were delivered in HRA, CS, LA and PVs respectively. For the patients who failed to induce AF, burst stimuli were used. Results 11 AF generating sites, which induced by S1S2 and S1S2S3 programmed stimuli, could be confirmed by identification of the earliest regions of atrial activation for the first AF cycle. However, 1 AF obtained by 260 ms RR interval burst stimuli, affirmed by shortest activation cycle length. All confirmed 12 AF original sites were original as following: RA (n=4), LA (n=1), CS (n=2); PVs (n=5). Among the 5 PVs original sites, 3 was from left superior pulmonary vein, while the other 2 were from right superior pulmonary vein and left inferior pulmonary respectively. Conclusion PVs could be the ectopic origin of valvular AF.

Objective To prepare and identify anti‐CD47 monoclonal antibodies .Methods The gene fragment of CD47 was am‐plified by polymerase chain reaction and cloned into prokaryotic expressing vector pET‐32a(+ ) .Purified reconstructed protein was used to immunize BALB/c mice .The immunized spleen cells were isolated and fused with Sp2/0 cells .After screened ,hybridomas secreting anti‐CD47 monoclonal antibody were acquired .Biological activities of antibodies were investigated by Western blot and flow cytometry .Results The recombinant CD47 extracellular domain protein was successfully expressed in BL21 ,and certificated by sodium dodecyl sulfate polyacrylamide gel electropheresis and Western blot .Data of flow cytometry detection demonstrated that the antiserum had high affinity to CD47 protein .Conclusion Recombinant CD47 and its monoclonal antibody ,with high affinity , were successfully prepared ,which could provide reliable tools for the future study of CD47 .

The purpose of the current study was to detect the potential therapeutic role of a survival benefit for women with advanced and recurrent endometrial carcinoma for their poor prognosis.A number of published studies for women with advanced and recurrent endometrial cancers were reviewed.We found that surgery had been the primary treatment of choice for an endometrial carcinoma.Where disease has spread to the uterine cervix,extended or radical surgery may be curative.The systematic lymph node resection improves the survival of women with intermediate/high-risk endometrioid uterine cancer,especially non-endometrioid carcinoma.The omentectomy may be beneficial for non-endometrioid cancer.A number of studies report a survival benefit from surgical cytoreduction in women with advanced and recurrent disease,although the degree of surgical effort is required in order to achieve an optimal result varies.Laparoscopic and robotic surgical staging for uterine cancer might be considered as a standard of care for endometrial cancer without extra-uterine metastasis.Laparotomy should be the first choice for extra-uterine metastasis and recurrent disease.Adjuvant radiotherapy and chemotherapy have a potential role in the management of high-risk,advanced,and recurrent disease.Efficacy of targeted and endocrinal treatment in women with advanced and recurrent endometrial cancer has been proved.